^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gallbladder Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Neoadjuvant therapy (for gallbladder cancer only)…Other recommended regimens…single agents…Capecitabine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Gallbladder cancer... the recommended dose of radiotherapy is 45 Gy in fractions of 1.8 or 2 Gy with concurrent 5-fluorouracil (5-FU) or capecitabine [IV,C].
    DOI:
    10.1093/annonc/mdw324
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

    Published date:
    05/01/2019
    Excerpt:
    ...cholangiocarcinoma or muscle-invasive gallbladder cancer…patients were randomly assigned 1:1 to receive oral capecitabine…median overall survival was 53 months (95% CI 40 to not reached) in the capecitabine group and 36 months (30-44) in the observation group (adjusted HR 0·75, 95% CI 0·58-0·97; p=0·028).
    DOI:
    10.1016/S1470-2045(18)30915-X
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study

    Excerpt:
    Patients with completely-resected cholangiocarcinoma (CCA) or gallbladder cancer...were randomized 1:1 to Cape...In the per-protocol analysis (Cape n = 210, Obs n = 220) median OS was 53m (95%CI 40, NR) for Cape …Median RFS (ITT) was 25m (95%CI 19, 37) for Cape…Cape improves OS in BTC when used as adjuvant…
    DOI:
    10.1200/JCO.2017.35.15_suppl.4006